899 related articles for article (PubMed ID: 11712805)
1. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
3. [Molecular genetic progression on nasopharyngeal carcinoma].
Shao JY; Zeng WF; Zeng YX
Ai Zheng; 2002 Jan; 21(1):1-10. PubMed ID: 12500388
[TBL] [Abstract][Full Text] [Related]
4. Frequent allelic loss at the FRA3B site in endemic nasopharyngeal carcinoma: association with clinical features and Epstein-Barr virus infection.
Deng YF; Zhou DN; Lu YD
J Laryngol Otol; 2007 Nov; 121(11):1073-8. PubMed ID: 17359554
[TBL] [Abstract][Full Text] [Related]
5. High frequency loss of heterozygosity on the long arms of chromosomes 13 and 14 in nasopharyngeal carcinoma in Southern China.
Shao J; Li Y; Wu Q; Liang X; Yu X; Huang L; Hou J; Huang X; Ernberg I; Hu LF; Zeng Y
Chin Med J (Engl); 2002 Apr; 115(4):571-5. PubMed ID: 12133301
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
Ling W; Cao SM; Huang QH; Li YH; Deng MQ
Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
[TBL] [Abstract][Full Text] [Related]
7. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide allelotype analysis of sporadic primary nasopharyngeal carcinoma from southern China.
Shao JY; Wang HY; Huang XM; Feng QS; Huang P; Feng BJ; Huang LX; Yu XJ; Li JT; Hu LF; Ernberg I; Zeng YX
Int J Oncol; 2000 Dec; 17(6):1267-75. PubMed ID: 11078815
[TBL] [Abstract][Full Text] [Related]
9. [Precise map of allelic loss on chromosome 3p14 in nasopharyngeal carcinoma].
Deng Y; Tian F; Yang X; Xie D; Lu Y; Shao X; Chen Z
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2000 Oct; 35(5):391-3. PubMed ID: 12768747
[TBL] [Abstract][Full Text] [Related]
10. Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma.
Luo YL; Ou GP; Chi PD; Liang YN; Liu YH; Huang MY
Ai Zheng; 2009 Jan; 28(1):76-8. PubMed ID: 19448423
[TBL] [Abstract][Full Text] [Related]
11. Investigation of allelic imbalances on chromosome 3p in nasopharyngeal carcinoma in Tunisia: high frequency of microsatellite instability in patients with early-onset of the disease.
Trimeche M; Braham H; Ziadi S; Amara K; Hachana M; Korbi S
Oral Oncol; 2008 Aug; 44(8):775-83. PubMed ID: 18206419
[TBL] [Abstract][Full Text] [Related]
12. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
[TBL] [Abstract][Full Text] [Related]
13. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity and specificity of Epstein-Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review.
Tsang RK; Vlantis AC; Ho RW; Tam JS; To KF; van Hasselt CA
Head Neck; 2004 Jul; 26(7):598-602. PubMed ID: 15229902
[TBL] [Abstract][Full Text] [Related]
17. High resolution allelotype of microdissected primary nasopharyngeal carcinoma.
Lo KW; Teo PM; Hui AB; To KF; Tsang YS; Chan SY; Mak KF; Lee JC; Huang DP
Cancer Res; 2000 Jul; 60(13):3348-53. PubMed ID: 10910036
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of IgG and IgA type antibodies to capsid and early antigens of the Epstein-Barr virus in the diagnosis of nasopharyngeal carcinoma].
Mendoza J; Rojas A; de la Rosa M; Amador JM; Expósito J; Esquivias J
Med Clin (Barc); 1991 Nov; 97(16):609-11. PubMed ID: 1662737
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
